VH032-cyclopropane-F Synthesis Route

VH032-cyclopropane-F Synthesis

VH032-cyclopropane-F (Synonyms: (2S,4R)-1-((S)-2-(1-Fluorocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide)

VH032-cyclopropane-F is the VH032-based VHL ligand. VH032-cyclopropane-F can be connected to the ligand for protein (e.g., SMARCA BD ligand) by a linker to form PROTACs (e.g., PROTAC 1). PROTAC 1 is a partial degrader of SMARCA2 and SMARCA4.

VH032-cyclopropane-F

Item No. BA92829
CAS No. 2306193-99-5
Purity: 95%

50mg

＄190.00

100mg

＄290.00

250mg

＄523.00

＄1,718.00

Quantity

Add to Cart

Buy Now

VH032-cyclopropane-F Synthetic Route

AB45102

CAS: 693-95-8

AB45102

CAS: 693-95-8

BA57954

CAS: 1448190-10-0

AX14340

CAS: 1448190-11-1

Al68087

CAS: 630421-46-4

BL34970

CAS: 2247480-45-9

BH87071

CAS: 2244684-40-8

CAS: 137081-41-5

BA92829

CAS: 2306193-99-5

1.1: potassium acetate; palladium diacetate / N,N-dimethyl-formamide / 110 °C / Sonication; Inert atmosphere
2.1: lithium aluminium tetrahydride / tetrahydrofuran / 5 h / -10 - 20 °C / Inert atmosphere
3.1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 0.5 h / 20 °C / Cooling with ice; Inert atmosphere
3.2: 5 h / -40 - 20 °C / Inert atmosphere
4.1: potassium carbonate / methanol / 12 h / 20 °C
5.1: hydrogenchloride / mathanol / 2 h / 20 °C
6.1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 0.5 h / 20 °C / Cooling with ice

Order VH032-cyclopropane-F Intermediates

{{item['cas']}} | {{item['name']}}

MF:{{item['mf']}} MW:{{item['mw']}}

Download SDS

Catalog No.

Pack Size

Purity

Availability

Price

${{getUSMoneyFormat(sku['price'])}}

Add to Cart

Buy Now

References

1.Current Patent Assignee: NURIX THERAPEUTICS - WO2023/69514, 2023, A2. 
2.Farnaby W, et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol. 2019 Jul;15(7):672-680. 

3.Liu J, et al. FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer. Exp Cell Res. 2021 Nov 15;408(2):112868.